These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8908379

  • 1. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Rosenstock J, Samols E, Muchmore DB, Schneider J.
    Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
    [Abstract] [Full Text] [Related]

  • 2. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
    Goldberg RB, Holvey SM, Schneider J.
    Diabetes Care; 1996 Aug; 19(8):849-56. PubMed ID: 8842603
    [Abstract] [Full Text] [Related]

  • 3. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
    Skillman CA, Raskin P.
    Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
    [Abstract] [Full Text] [Related]

  • 4. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LD.
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J, Bugos C, Dirnberger G, Atherton T.
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 11. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [Abstract] [Full Text] [Related]

  • 12. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
    Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Rosskamp R.
    Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, Feinglos MN, HARMONY 3 Study Group.
    Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.